Europe

TURKU – FINLAND, 30 September 2019 – Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today announces details from a poster discussion presentation held at the European Society of Medical Oncology 2019 Congress to showcase recent data from its ongoing MATINS study.

4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces that it has appointed Philippe Fauchet, OBE, as a Venture Partner based in Japan.

Centauri Therapeutics, an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences

The payment of USD 14.3 million corresponds to the USD 11.6 million in damages plus interest awarded to Adocia in August 2018 by an American Arbitration Association Panel presiding over Adocia’s arbitration claims against Eli Lilly

Hutchison China MediTech Limited presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic at the 2019 European Society for Medical Oncology Congress.

C4X Discovery Holdings plc is pleased to note Indivior PLC’s announcement that the National Institutes of Health has granted Indivior’s application entitled “Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder” pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose.

Sareum Holdings plc is pleased to announce that it will present new preclinical data from its SDC-1802 TYK2/JAK1 inhibitor cancer research programme at the American Association for Cancer Research National Cancer Institute European Organisation for Research and Treatment of Cancer International Conference, to be held 26-30 October 2019 in Boston, USA.

When you think about personalized cancer care, those annoying fruit flies in your kitchen are likely not the first things that come to mind. But they are exactly what My Personal Therapeutics uses to create personalized cancer treatment combinations.

Shares of Dova Pharmaceuticals are up more than 38% in premarket trading after Sobi announced its intentions to acquire the company for $915 million.

Phase 1/2, open-label, multicenter study ongoing to evaluate KY1044 as a single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with advanced malignancies Cambr